Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Farmers Insurance
QuintilesIMS
Fuji
Boehringer Ingelheim
Baxter
Deloitte
UBS
Julphar

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,097,648

« Back to Dashboard

Which drugs does patent 8,097,648 protect, and when does it expire?

Patent 8,097,648 protects HALAVEN and is included in one NDA.

This patent has thirty-eight patent family members in twenty-one countries.
Summary for Patent: 8,097,648
Title:Methods and compositions for use in treating cancer
Abstract: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.
Inventor(s): Littlefield; Bruce A. (Andover, MA), Towle; Murray J. (Auburn, NH), Seletsky; Boris M. (Andover, MA), Yu; Melvin J. (Andover, MA), Zheng; Wanjun (Londonderry, NH)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:11/282,505
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,097,648

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,097,648

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,469,182 Intermediates in the preparation of macrocyclic analogs ➤ Try a Free Trial
6,214,865 Macrocyclic analogs and methods of their use and preparation ➤ Try a Free Trial
8,148,554 Methods and compositions for use in treating cancer ➤ Try a Free Trial
7,470,720 Methods and compositions for use in treating cancer ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,097,648

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 502932 ➤ Try a Free Trial
Australia 2003284242 ➤ Try a Free Trial
Australia 4573999 ➤ Try a Free Trial
Australia 762998 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Teva
Colorcon
Chinese Patent Office
McKesson
McKinsey
Express Scripts
Cantor Fitzgerald
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.